| http://www.w3.org/ns/prov#value | - Bleeding risk clouds Merck's hopes for vorapaxar franchise - FierceBiotechDate: Mar 26, 2012Category: HealthDr. David Morrow of Brigham and Women's Hospital in Boston told the gathering at the American College of Cardiology that 11.2% of the patients taking vorapaxar experienced a cardiovascular event, such as heart attack, stroke or death, compared to 12.4% of the patients in the control arm.
|
